B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

NADK

MOLECULAR TARGET

NAD kinase

UniProt: O95544NCBI Gene: 652202 compounds

NADK (NAD kinase) is targeted by 2 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting NADK

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1epigalocatechin gallate5.40220
2egcg1.393

About NADK as a Drug Target

NADK (NAD kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 2 compounds with documented NADK interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

NADK inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.